Literature DB >> 21454846

Rampant caries from oral transmucosal fentanyl citrate lozenge abuse.

Louis Mandel1, Michele J Carunchio.   

Abstract

BACKGROUND: Oral transmucosal fentanyl citrate lozenges (lollipops) are indicated for the oral management of breakthrough cancer pain. When abused, these sucrose-containing lozenges can cause rampant dental caries. CASE DESCRIPTION: The authors examined a 19-year-old man whose dentist referred him because of total dental coronal destruction. After the authors questioned the patient, they concluded that his frequent oral use of sucrose-containing opioid fentanyl citrate lozenges across a three-year period caused the dental condition. CLINICAL IMPLICATIONS: Dentists should be aware that oral transmucosal fentanyl citrate lozenges are being prescribed off-label for the control of pain from nonmalignant sources. Fentanyl citrate's effective analgesic potency can lead to misuse and potential abuse. Early recognition of its misuse could prevent severe dental caries and the need for extensive dental restoration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454846     DOI: 10.14219/jada.archive.2011.0195

Source DB:  PubMed          Journal:  J Am Dent Assoc        ISSN: 0002-8177            Impact factor:   3.634


  4 in total

Review 1.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 2.  Fentanyl for the treatment of tumor-related breakthrough pain.

Authors:  Helmar Bornemann-Cimenti; Mischa Wejbora; Istvan S Szilagyi; Andreas Sandner-Kiesling
Journal:  Dtsch Arztebl Int       Date:  2013-04-19       Impact factor: 5.594

3.  Micromonas micros: A rare anaerobic cause of late implant failure following spinal surgery.

Authors:  Garret L Sobol; John I Shin; Michael J Vives; Lisa L Dever; Colin B Harris
Journal:  J Spinal Cord Med       Date:  2019-10-30       Impact factor: 1.985

4.  Improvement of Pain Relief of Fentanyl Citrate Drug Encapsulated in Nanostructured Lipid Carrier: Drug Formulation, Parameter Optimization, in vitro and in vivo Studies.

Authors:  Mohammad Amin Bahrami; Nafiseh Farhadian; Mohammad Karimi; Arash Forouzan; Kambiz Masoumi
Journal:  Drug Des Devel Ther       Date:  2020-05-25       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.